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ABSTRACT
Introduction: The appraisal of medicines is often a complex and iterative process. We compared
the health technology assessment (HTA) process in England and France taking as a case study the
example of ixazomib for multiple myeloma.
Methods: We undertook an analysis of eight relevant published documents identifed from the
websites of the French and English HTA bodies (HAS and NICE, respectively). We analyse patients’
availability of ixazomib resulting in the different stages of the appraisal process.
Results: We identified differences in the assessment, one of these being the use of an appraisal
scope in England allowing the differentiation of populations and comparators according to
previously approved treatments. Ixazomib became available earlier in France as part of an early
access programme, but the availability was soon discontinued for newly eligible patients follow-
ing an HAS determination that Ixazomib yielded no additional benefit. This opinion resulted in
long pricing discussions. In England, despite the absence of an early access programme and
following a process that included cost-effectiveness evaluation combined with pricing discus-
sions, the medicine was fairly rapidly recommended for use.
Conclusions: Differences in the HTA process may result in appreciable differences in time from
marketing authorisation to health service adoption of newly licensed drugs.
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Introduction
There has been considerable public concern expressed
about perceived delays in making new medicines avail-
able for sick patients. In the European union, the grant-
ing of marketing authorisation denotes that the
benefit/risk balance for a new medicine is deemed
favourable by the European Medicines Agency (EMA).
However, decisions about costs and reimbursement by
Health Insurance Systems are taken by each individual
State member based on advice from country-specific
Health Technology Assessment (HTA) bodies.
Ixazomib is an orally administered proteasome inhibi-
tor which was approved by the EMA in November 2016
for treating patients with relapsed or refractory multiple
myeloma (RRMM) [1]. It is used in combination with lena-
lidomide-dexamethasone (LEN-DEX).
Since the marketing authorisation of ixazomib in
RRMM, a number of EU countries (e.g., Germany,
Austria, and Denmark) have provided a positive opinion
on its reimbursement [2].
As of July 2019, ixazomib is available for patients
with RRMM via national reimbursement schemes in
both France and England, albeit there are more restric-
tions in England according to the number of prior lines
of treatment. This current end result in the two coun-
tries does not fully reflect if there have been potential
differences in the HTA processes involved.
The National Authority for Health (HAS) in France
and the National Institute for Health and Care
Excellence (NICE) in England have a central functional
role in the assessment of health technologies and in
ensuring rational price settings.
Our objectivewas to compare health technology assess-
ment in France and England and to assess their differences
and limitations using the example of ixazomib as a case
study. We define the health technology assessment pro-
cess in terms of the main steps between the start of
appraisal until the final decision on reimbursement.
Our choice of ixazomib derived from the involve-
ment of several authors in the appraisal of ixazomib
by NICE.
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Methods
First, we provide an overview of the national drug
assessment processes in France and England, and then
we present the methods for our case-study to compare
HTA and the decision-making processes for ixazomib in
both countries.
Overview of national drug assessment in France
and England
The English Health Technology Assessment (HTA) process
applies to new medicines which have been screened and
assessed as likely to incur significant increased expendi-
tures for the National Health Service (NHS) [3].
Conversely, in France, the process of HTA is systema-
tic for all newly available medicines, whether marketing
authorisation is granted nationally or at a European
level essentially through a centralized procedure [4].
The major difference between the two processes lies in
the paradigm of assessment. In England, NICE is asked to
determine first whether the new drug is clinically effective
compared to standard of care, and second whether the
drug represents good value for money [5].
For this purpose, the cost-effectiveness of the drug is
examined against a threshold between £20,000 and
£30,000 per Quality Adjusted Life Years (QALY) gained
compared to appropriate comparator(s) [6]. As part of
this appraisal, companies are invited to propose commer-
cial access agreements to NHS England, which are taken
into account in assessing the cost-effectiveness of the
drug [7].
In France, the process follows several stages. First,
the Transparency Committee of the French HAS
assesses the level of actual medical benefit (SMR for
‘Service Médical Rendu’) on the basis of the clinical
effectiveness and safety profile of the drug together
with considerations of disease severity, and the drug’s
impact in terms of the quality of public health [8].
Next, should the SMR be judged sufficient, the same
committee appraises the level of improvement of med-
ical benefit (ASMR for ‘Amélioration du Service Médical
Rendu’) which accounts for the added clinical benefit of
the new drug relative to existing treatment(s). ASMR
ratings are given on a scale from I (major benefit) to
V (absence of/no additional benefit) [8]. Based on the
SMR/ASMR ratings provided by HAS, the next step is
the pricing discussion between the National Economic
Committee (CEPS for ‘Comité Economique des Produits
de Santé’) and the drug company [9]. Pricing discussion
encompasses the costs of the drug and the price of
comparators together with the anticipated number of
eligible patients [9].
Unlike the NICE process, HAS does not systematically
examine the cost-effectiveness of new drugs. An assess-
ment of cost-effectiveness in France is undertaken by
the Committee of Economic Evaluation and Public
Health (CEESP) of the French HAS, which is distinct
from the Transparency committee. Cost-effectiveness
evaluation is restricted to a] drugs deemed innovative
(defined as drugs for which Companies claim an ASMR
rating between I to III) and b] the likelihood the health
system will incur significant expenditures (defined as
those for which the anticipated yearly budget is at
least 20 million euros nationally) [10]. Opinions by
CEESP on the drug cost-effectiveness are taken into
account by the CEPS at the stage of pricing. There is
no French threshold to define whether a new technol-
ogy is cost-effective [11]. In this particular case Ixazomib
did not meet the two French criteria (a] and b]) requir-
ing a cost-effectiveness evaluation.
Methods of our case-study
The HTA process related to ixazomib was examined and
compared: all relevant documents within the internet
websites of NICE and HAS were identified and analysed.
For NICE, we identified the following relevant docu-
ments [12]: draft and final scope, committee papers,
appraisal consultation document (ACD), final appraisal
document (FAD), guidance. For HAS, we identified the
transparency committee opinion and the minutes of
transparency committee meetings [2]. A narrative
account is presented.
Results
Figure 1 depicts the main milestones of the technology
assessment of ixazomib in England and France and
shows the resulting decisions regarding the availability
of the drug for patients.
Just 6 months following the publication of the pivo-
tal phase III trial [13], and 1 month before ixazomib was
granted a marketing authorisation [1], France was the
first country allowing access to ixazomib to patients
with RRMM. This was possible through the patient
early access program also called ‘ATU’ for ‘Autorisation
Temporaire d’Utilisation’ which is one of the mainstays
of access to innovative medicines in France [14]. ATUs
can be issued by the French regulatory agency of med-
icines (ANSM) for individuals who cannot participate in
a clinical trial and where the product is expected to be
of benefit for the patient [15] and where no other
therapeutic option is available. As part of the access
program, patients are fully covered for the expenses by
the National Health Insurance system.
2 X. ARMOIRY ET AL.
Over the period October 2016-May 2017, 35 indivi-
dual patients benefited from ixazomib within this scope
[2]. However, from May, the 2nd 2017 onwards, ixazo-
mib was only made available for those who were
initiated prior to this date, which means the availability
of the drug to potentially further newly eligible patients
was no longer possible. The reason for discontinuation
for newly eligible patients at this time is not clearly
reported and may be related to the concomitant
appraisal of ixazomib by HAS [2].
The first appraisal committee meetings at NICE and
HAS took place in March 2017 andMay 2017, respectively.
Both NICE and HAS have assessed the clinical effec-
tiveness of ixazomib according to its label indication,
namely patients with multiple myeloma who failed at
least one prior regimen.
The evidence submitted by the manufacturer of ixa-
zomib (Takeda) to support the clinical effectiveness was
similar between jurisdictions and relied on the findings
from the Tourmaline MM1 (TMM-1) trial. TMM-1 is
a randomised controlled trial (RCT) that enrolled 771
RRMM patients who received either ixazomib and LEN-
DEX (IXA-LEN-DEN) or placebo-LEN-DEX as 2nd, 3rd or
4th line treatment [13]. The primary endpoint was pro-
gression-free survival (PFS) assessed by an independent
review committee (IRC) while overall survival (OS) was
a secondary endpoint.
Neither NICE nor HAS have identified major methodo-
logical issues with the design and the conduct of the TMM-
1 trial which was deemed of good quality. However,
a common source of concern pertained to the presence
of a treatment effect with ixazomib compared with pla-
cebo. The PFS Hazard Ratio (HR) based on the first interim
analysis (15 months follow-up) suggested a 26% reduction
in the risk of progression or death (HR 0.74, 95%CI 0.5, 0.94;
p = 0.012). However, further trial analyses which were not
part of the pre-specified statistical analysis plan, conducted
upon request by the US Food and Drug Administration
(FDA) using slightly more mature follow-up data (23
months median follow up), found a smaller treatment
effect of 18% risk reduction which was not statistically
significant (HR 0.82, 95% CI 0.67, 1.0; p = 0.054).
Given that the analyses of more mature data were
non-inferential, NICE and HAS acknowledged that, from
a formal statistical standpoint, PFS benefit had been
demonstrated, but both agencies commented that the
results based on PFS overall lacked robustness [2,12].
NICE and HAS highlighted the immaturity of TMM-1
trial data for analysis OS in both first and second interim
analyses; no benefit from adding ixazomib to LEN DEX
was observed (HR for death of 0.90, 95% CI 0.62, 1.32 and
0.87, 95% CI 0.64, 1.18, respectively). Longer-term follow-
up would be needed to draw conclusions on OS
outcomes.
A notable difference between French and English
assessments was the consideration of subgroup analyses
from the TMM-1 trial.
In France, the transparency committee in effect
assessed ixazomib strictly according to its label indica-
tion (patients with RRMM who received at least one
prior therapy and therefore examined evidence for the
entire TMM-1 population; no assessment was made
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Figure 1. Comparative availability over time of ixazomib for new patients with relapsed or refractory multiple myeloma between France
and England and main milestones of the appraisal. The red bars denote periods of time during which ixazomib was not reimbursed in
each country's health-care system, the green bars denote periods of time during which ixazomibwas reimbursed in each country’s health-
care system, the orange bar denotes potential uncertainty in the reimbursement of ixazomib.TMM-1 = Tourmaline MM1 trial; NICE =
National Institute for Health and Care Excellence; HAS = French High Health Authority; CDF = Cancer Drugs Fund; ASMR = improvement
of actual medical benefit; RRMM = relapsed refractory multiple Myeloma; ATU = Early Access Program.
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differentiating patients according to the number of
prior therapies received although TMM-1 trial subgroup
analyses according to number of prior therapies were
reported in the transparency committee document
these were not further commented upon and appar-
ently were not taken into consideration for decision-
making [16].
Conversely, the appraisal by NICE relied on a pre-
appraisal scoping document which indicated that the
assessment should be differentiated according to the
number of prior regimens received by patients [17]. This
was because not all comparator regimens were equally
recommended within the NHS with regard to the num-
ber of therapies previously received.
Interestingly, while bortezomib (with or without dex-
amethasone) was mentioned as the appropriate standard
in RRMM patients at the second line (one prior therapy) in
the NICE scope, lenalidomide-dexamethasone (LEN-DEX)
was deemed the most relevant comparator in patients at
the third or fourth line (two or three prior therapies).
Within this scope, IXA-LEN-DEX was to be assessed
against bortezomib-based regimens for the second line,
while it was to be assessed against LEN-DEX for third or
fourth line treatment.
In a first (non-final) appraisal, NICE concluded that IXA-
LEN-DEX did not represent good value for money com-
pared with bortezomib-based regimens; this conclusion
was based on results from indirect treatment comparisons
of benefit and on cost-effectiveness modelling. Similarly,
at first appraisal, IXA-LEN-DEX was not recommended for
third or fourth line therapy versus LEN-DEX; this was after
consideration of direct subgroup evidence from the TMM-
1 trial indicating a HR 0.62 (95% 0.45, 0.86) for PFS and
a trend for improved OS.
In subsequent submissions to NICE by the Company,
IXA-LEN-DEX was repositioned exclusively as a 3rd or 4th
line therapy, with LEN-DEX as the relevant comparator.
The resulting clinical effectiveness data coupled with
new price discounts, in the judgement of the appraisal
committee, rendered ixazomib potentialy cost-effective
for this sub-population.
Ixazomib was eventually recommended as a third/
fourth line option, not through routine commissioning,
but within the Cancer Drugs Fund (CDF) [18]. The prin-
ciple of the CDF is to allow further data collection with
the aim of diminishing clinical uncertainty [19]. On the
basis of these appraisal stages, it appears very unlikely
that NICE could recommend ixazomib in the absence of
differentiation of patients according to the number of
prior therapies and referral to the CDF.
In France, the Transparency Committee published an
opinion in July 2017 concluding that there was an
absence of medical benefit improvement for IXA-LEN-
DEX compared with LEN-DEX alone (ASMR rating of V)
[2]. In its submission to HAS, the Company Takeda claimed
an ASMR rating of IV for ixazomib [20]. Given the sub-
mitted evidence exhibiting a lack of robustness for effec-
tiveness in PFS and immaturity in OS data, an ASMR rating
of V for the label indication (i.e., no discrimination accord-
ing to the number of previous therapies) is unsurprising.
Since the additional cost of ixazomib had to be
considered against no treatment (LEN-DEX alone), no
pricing arrangements could be found at the time
between the French CEPS and the Company.
Eventually, in October 2018 a final decision was made
on the list price of ixazomib in France [21]. Thismeans that
access to ixazomib for potential newly eligible patients
was discontinued for 18 months (Figure 1).
Had the transparency committee considered clinical
effectiveness data differentiated according to the num-
ber of prior therapies, it appears likely that the same
ASMR rating of V would have pertained for second-line
treatment.
However, the ASMR rating could have been more
favourable if results observed in patients with more
prior treatments had been included. In such
a situation, presumably, a much earlier price arrange-
ment might have been arrived at allowing the reimbur-
sement of ixazomib in such a subgroup of patients.
Discussion
We have emphasised that access to ixazomib occurred
much earlier in France compared to England thanks to
the ATU programme, but that it subsequently became
unavailable to newly eligible patients for a long period
as pricing negotiations were ongoing between the
Company and the French CEPS.
It may seem paradoxical that a new drug is judged
so promising that it is made available under the ATU
programme, but it is eventually granted an ASMR rating
of V even though the same set of data on clinical
effectiveness was used. However, based on the sub-
mitted evidence, we would agree that the ASMR of
V granted to ixazomib appeared appropriate.
Although recently the criteria used to judge ASMR
have been more clearly explained [22], this paradoxical
situation may suggest the adoption of a more consis-
tent policy of access to innovation in France involving
ANSM and HAS and an appraisal process differentiating
the populations most likely to benefit from a drug.
The uncertainty around clinical effectiveness estimates,
especially for OS because of the immaturity of data, was
highlighted in appraisals. This likely influenced the final
opinion provided by HAS (ASMR rating of V). In such
situations, temporary mechanisms of funding such as
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the one in place with the CDF in England are worthy of
consideration, i.e., allowing patients to benefit from inno-
vative medicines whilst collecting data with the aim of
reducing uncertainty. This sort of funding source might
usefully be implemented in France; however, analyses of
data should be mandatory within a specified timeline.
The two appraisals conducted in France and England
for ixazomib can be compared according to pricing. The
basic NHS list price of ixazomib is £6,336 (excluding VAT)
for a pack of three capsules irrespective of the strength
[12]. The discounted price included in the commercial
access agreement is confidential but presumably much
lower. The final ICER produced under the proposed com-
mercial access agreement has been publicly disclosed
(£31,691 per QALY gained compared to LEN-DEX alone)
which is useful to help understand the decision-making.
In France, the officially published price in October 2018
is €3,875 (excluding VAT) for three capsules [21]. It is
highly likely that this price is a discounted one obtained
after pricing negotiation, which denotes an apparently
higher degree of transparency in France. In the absence
of formal cost-effectiveness evaluation, it is unclear what
factors were accounted for in the pricing of ixazomib in
France. This seems particularly important given the poor
ASMR rating (ASMR of V) the drug received compared to
LEN-DEX alone. Indeed, while ASMR ratings of V can be
provided for new medicines compared to other active
agents, here the ASMR rating of V for ixazomib was
given compared to LEN-DEX alone, which denotes no
additional benefit compared to placebo.
It is important to bear in mind that in France, as in
other countries, the published price following negotia-
tions is usually not the real one, since prices are deter-
mined based on a price/volume agreement, which
involves confidential national rebates.
Although we have pointed to a more direct and sim-
plified availability of ixazomib in England, it is important to
highlight the more restricted circumstance of use in
England since the CDF only allows funding of the drug
for RRMM patients at the third or fourth line. More speci-
fically, there are issues associated with patients treated at
the second line. Indeed, LEN-DEX is currently no longer
funded at this stage through the CDF and this drug regi-
men is only used in patients at the third or fourth line.
Similarly, retreatment with bortezomib at the second line
is no longer funded through the CDF. There is, therefore,
a lack of recommended therapies for patients within the
NHS at second line who were previously treated with
bortezomib-based regimens at first line [12].
Our work has some limitations. The main one is that
our method of analysis did not include interviews with
stakeholders, it is possible that we have not fully captured
the full complexity of the decision-making process. This
includes pricing discussions on commercial access agree-
ments which remain confidential to public observers. We
have only focussed on a single example so that our obser-
vations may not as widely generalizable as we would wish.
Based on our comparison of England and France, our
view is that cost-effectiveness evaluation could become
more systematically used in France allowing a more trans-
parent process of pricing based on a defined willingness to
pay threshold.
Further research is required to comprehensively
assess the usefulness of the early access program for
innovative drugs in France.
Since English funding through the CDF is said to be
provisional, it will be interesting to observe the next
review of ixazomib by NICE, based on more mature
clinical effectiveness data. As any other drug, it is also
expected that ixazomib will be re-reviewed by the
French HAS in the near future.
Althoughwe have indicated amore rapid final decision
taken in England compared to France, the decision of
reimbursement was taken even more rapidly in other
European countries since ixazomib was reimbursed in
Germany, Austria, and Denmark less than 3 months fol-
lowing EMA approval.
In conclusion, based on our specific observation of
France and England, it appears that differences in the
HTA process such as the differentiation of populations
and/or comparators according to previous treatments can
result in appreciable differences in time from marketing
authorisation to health service adoption of newly licensed
drugs.
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